Interleukin-17 (IL-17) is a pro-inflammatory cytokine and is involved in the development of many diseases. Recent studies have revealed that IL-17-producing cd T cells (cd17 cells) in addition to IL-17-producing CD4 + T cells [T helper type 17 (Th17) cells] are often the main producers of IL-17 in mouse models of inflammatory diseases. cd T cells are functionally committed during intra-thymic differentiation. cd thymocytes capable of producing IL-17, which express the transcription factor retinoic-acidreceptor-related orphan receptor ct and the signature cytokine receptor IL-23R, leave the thymus, and produce IL-17 rapidly by the stimulation with IL-1b and IL-23 in the periphery. Therefore, cd17 cells play important roles in the early phase of host defence against pathogens and in inflammatory diseases. cd T cells that can produce IL-17 are also increased in the skin of patients with psoriasis and in peripheral blood of patients with ankylosing sclerosis. Indeed, the therapy targeting IL-17 has been approved or is in clinical trials, and proved to be very efficient to treat psoriasis, psoriatic arthritis and ankylosing sclerosis. In this review, we discuss recent knowledge about the pathophysiological function of cd17 cells in infection and inflammatory diseases and therapeutic advances targeting IL-17.
Introduction
Interleukin-17A (IL-17A, called 'IL-17' hereafter) is a member of the IL-17 family. 1 The binding of IL-17 to the heterodimeric receptor consisting of IL-17RA and IL-17RC subunits transduces signals to activate a group of cytokines and chemokines such as tumour necrosis factor, IL-1, IL-6, granulocyte colony-stimulating factor, CXCL1 and CXCL2 through activation of the actin related gene 1-TNF receptor associated factor 6-nuclear factor-jB axis in the downstream. 1 The function of IL-17 is pleiotropic. It plays a crucial role in the host defence against bacterial and fungal infection by inducing pro-inflammatory cytokines and chemokines, recruiting neutrophils, and activating T cells and B cells.
1,2 Mice deficient for IL-17RA are highly susceptible to Klebsiella pneumoniae 3 and IL-17-deficient mice are susceptible to bacterial and fungal infection. 4 ,5 Interleukin-17 is also implicated in various inflammatory/autoimmune disease models such as experimental autoimmune encephalomyelitis (EAE), arthritis in IL-1 receptor antagonist-deficient (Il1rn -/-) mice and imiquimod-induced psoriatic dermatitis in mice.
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and anti-IL-17RA antibodies are effective to treat patients with psoriasis and psoriatic arthritis. [11] [12] [13] Interleukin-17 is also important for the maintenance of intestinal barrier integrity and its functional deficiency causes the development of inflammatory bowel diseases. [14] [15] [16] In contrast, suppression of IL-17F, another highly homologous member of IL-17 family, is suggested to be beneficial for the treatment of inflammatory bowel diseases. 17 Interleukin-17 was initially found to be produced by helper CD4 + T [T helper type 17 (Th17)] cells, but subsequent studies showed that innate immune cells and innate-like immune cells are also important sources of IL-17 in inflamed tissues. 18, 19 cd T cells are the principal source of IL-17 in some mouse inflammatory disease models and thereby exert considerable impact on disease development and progression. [20] [21] [22] [23] [24] The IL-17-producing cd T cells (cd17 cells) share many features with Th17 cells, such as cell surface expression of IL-23R and CCR6 and the expression of transcriptional factor retinoic-acidreceptor-related orphan receptor ct (RORct). To induce IL-17, naive T cells have to differentiate into Th17 cells in the periphery by the stimulation with T-cell receptor (TCR) and cytokines such as IL-6 and transforming growth factor-b. In contrast, the functional potential to produce IL-17 in cd17 cells is already established during intra-thymic development [25] [26] [27] and IL-17 is directly induced by IL-23 and IL-1 without TCR stimulation in the periphery. This pre-programming contributes to rapid IL-17 production in peripheral tissues in the early phase of pathogen infection. In this review, we would like to introduce the roles of cd17 cells in inflammatory diseases and recent therapeutic advances targeting IL-17.
cd T-cell subsets and their development cd T cells and ab T cells are generated in thymus from common progenitor cells. Unlike ab T cells, cd T cells are functionally committed during intra-thymic differentiation. 28, 29 In mice, the TCR-c locus consists of seven Vc (Vc1-Vc7) genes (Heilig & Tonegawa's nomenclature 30 ) that are closely correlated with the effector function, although Vc3 is a pseudogene in most mouse strains. 31 Production of IL-17 is mostly limited to Vc4 + and Vc6 + cd T cells, 32 although Vc1 + cd T cells also produce IL-17 in some cases. 33 On the other hand, interferon-c (IFN-c) production is associated with Vc1 + , Vc5 + and Vc7 + cd T cells. Although overall gene expression patterns are similar between Vc4 + and Vc6 + subsets, 34 each subset has distinct features (Fig. 1 ). Vc6 + cd T cells express the invariant Vc6/Vd1 TCR, develop only in the late embryonic thymus and preferentially localize to the uterus, vagina, lung, dermis and peritoneal cavity. 35, 36 On the other hand, Vc4 + cd T cells develop in both fetal and adult thymus, have more diverse TCR repertoire and reside in the dermis, lung, liver and secondary lymphoid organs. 37, 38 In addition to RORct, transcription factors such as Blk, 39 Hes-1, 40 nuclear factor-jB, 41 Sox4 and Sox13 42 are also important for cd17 cell development. Transforming growth factor-b and IL-7 are required for cd17 thymocyte development and expansion, respectively. [43] [44] [45] Epigenetic and transcriptional regulation during cd17 cell differentiation has been reviewed elsewhere. 46 cd thymocytes capable of producing IL-17, which express the transcription factor RORct and the signature cytokine receptor IL-23R, 34 leave the thymus as functionally committed cells, 47 and produce IL-17 directly by the stimulation with IL-1b and IL-23 in the periphery. Although IL-23R is constitutively expressed on cd17 cells, the expression of IL-1R in peripheral cd17 cells is tissuedependent. 48 In addition to IL-1R and IL-23R, the expression of scavenger receptor 2 (Scart 2) 49 and CCR6, 27 and the lack of CD122 25 and CD27 expression 26 are often used as markers for cd17 cells, with the exception for IL-17-producing Vc1 + cd T cells. 33 These phenotypes, established during thymic development, distinguish cd17 cells from IFN-c-producing cd T (cdIFN-c) cells (Fig. 2) . cd17 cells that develop before birth persist in adult mice as self-renewing, long-lived cells. 50 The requirement of TCR signalling for cd17 cell development is not fully understood. 51 Early T-cell precursors can produce IL-17 before TCR recombination 50 and Sox4 and Sox13 are expressed before activation with TCR 42 Antigen-naive cd T cells in the thymus differentiate into IL-17 producers, whereas antigen-experienced cells make IFN-c. 28 Furthermore, Vc5 + Vd1 + thymocytes induce Egr3 upon recognition of Skint-1 expressed on thymic epithelial cells, resulting in the induction of IFN-c expression and suppression of RORct and Sox13 expression. 52 Thus, TCR signalling seems to direct cd thymocytes to differentiate into IFN-c-producing cd T cells by suppressing the 'default' IL-17 programme.
The mechanism of IL-17 production in cd17 cells cd17 cells are functionally committed in the thymus, producing IL-17 in the periphery after stimulation with IL1b and IL-23 without additional TCR stimulation. 21, 24 The 'ready-to-go' phenotype of cd17 cells is especially efficient for early-stage pathogen clearance. A combination of IL-1b and IL-23, but not IL-1b or IL-23 alone, is required to induce IL-17 by cd17 cells. 20 Further study revealed that IL-23 is required for the induction of IL-1R, and IL-1b is essential for the induction of IL-17. 20 However, because IL-1b alone does not induce IL-17 production in Il1rn À/À mouse-derived splenic cd T cells 20 and in normal peritoneum-and lung-derived cd T cells, in which high levels of IL-1R are expressed, 48 IL-23 may play other roles than up-regulating IL-1R in the induction of IL-17 expression in cd T cells. In this context, RORct expression is up-regulated by IL-1b and IL-23 in a synergistic manner. 20 The inflammatory cytokine IL-18, 53 complement C5a, 54 the ligand of Toll-like receptors 1 and 2, and dectin-1 55 also induce IL-17 in collaboration with IL-23. Although cd17 cells typically behave as innate-like immune cells, IL-17 induction by TCR signalling is also reported. Mouse and human cd T cells recognize an algal protein, phycoerythrin, and differentiate to IL-17-producing cells after immunization by this antigen. 56 These studies, in combination with cell reconstitution studies, 50 suggest that 'natural' cd17 cells (Vc6 + and part of Vc4 + ) acquire IL-17-producing ability in the fetal thymus and do not require TCR stimulation in the periphery, whereas 'inducible' cd17 cells (mostly Vc4 + ) that develop after birth produce IL-17 upon encounter with antigens 57 ( Fig. 1) . Notably, phycoerythrin antigen stimulation induces IL-1R expression on cd T cells. 56 Therefore, cd TCR activation may make 'inducible' cd17 cells respond to IL-1b and IL-23 to induce IL-17. A similar activation mechanism is also suggested in Th17 cell differentiation; IL-1R expression is increased upon Th17 differentiation from naive CD4 + T cells, 58 and the polarized Th17 cells can produce IL-17 by IL-1 and IL-23 in the absence of TCR stimulation. 59 However, the molecular basis for the 'inducible' state and the difference between 'naive' and 'inducible' cd17 cells remain to be elucidated.
The pathogenic roles of cd17 cells in mouse inflammatory disease models
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-/-mice show significantly reduced severity in various inflammatory and autoimmune disease models, such as collagen-induced arthritis, 6 Il1rn À/À mouse arthritis, 7 EAE 8 and imiquimod (IMQ)-induced skin inflammation, 9, 10 suggesting critical roles of IL-17 in inflammatory/ autoimmune diseases. cd17 cells are detected in inflamed tissues of these disease models. However, the roles of cd T cells in the development of diseases and the responsible cd subset are different in different models (Table 1) . As no conditional Il17 -/-mice in which the Il17 gene is deleted specifically in cd17 cells are available, the pathogenicity of cd17 cells has been analyzed using cd T-cell-deficient mice (Tcrd -/-mice) or the cd17 cell subset from these disease models.
In the collagen-induced arthritis model, both cd17 cells and Th17 cells are found in joints and draining lymph nodes and the majority of the cd17 cells are Vc4 + / Vd4 + . 22 21 Interleukin-23-activated cd T cells also prevent regulatory T-cell function, resulting in the enhancement of ab T-cell responses and EAE development. 61 A pathogenic role for cd17 cells is implicated in psoriasis. Vc5 + /Vd1 + cd T cells, also called dendritic epidermal T cells, uniquely residing in epidermis produce IFN-c and participate in immunosurveillance. 62 On the other hand, dermis contains Vc4 + and Vc6 + subsets responsible for IL-17 production. The pathogenicity of cd17 cells in psoriasis is well studied in a mouse model of psoriasis, IMQ-induced dermatitis. 9, 23 Imiquimod is a Toll-like receptor-7/8 agonist and induces IL-17-dependent psoriasiform dermatitis by inducing IL-23. 63 The IMQ-induced epidermal thickening is significantly decreased in Tcrd -/-mice, but not in Tcrb -/-mice. 9 Development of dermatitis is also suppressed by the deficiency of innate lymphoid cells (ILCs), suggesting that cd17 cells and IL-17-producing group 3 ILCs (ILC3s) are responsible for the development of psoriasiform dermatitis in mice. 9, 23 Both Vc4 + and Vc6 + subsets produce IL-17 after IMQ treatment of the skin. 35 Skin inflammation after IMQ treatment is significantly attenuated in Sox4 À/À mice, in which dermal Vc4 + but not dermal Vc6 + cd T cells are greatly reduced. 42 Congenic CD45.1 + (B6.SJL) mice with naturally occurring Sox13 mutation, in which dermal Vc4 + cd17 cell development is defective, develop attenuated ear skin inflammation with less acanthosis and fewer epidermal neutrophil pustules upon treatment with IMQ. 64 However, both wildtype bone marrow cell-reconstituted mice and neonatal thymocytes plus CD45.1 + (B6.SJL) bone marrow cellreconstituted mice (in which Vc4 + and Vc6 + cells are predominant, respectively) similarly develop epidermal thickening with increased dermal cd17 cells and neutrophil infiltration, suggesting that both cd17 subsets induce IMQ-induced dermatitis. 35 Interleukin-17F and IL-22 from cd T cells are also pathogenic in IMQ-induced dermatitis. 9 Interleukin-23-induced skin inflammation is another model of psoriasis. The IL-17-producing dermal cells are significantly reduced in Tcrd À/À mice accompanied with less skin inflammation and acanthosis, whereas Tcra À/À mice normally develop dermatitis, 23 suggesting that cd17 cells play major roles in the pathogenesis of psoriatic dermatitis in this model. The involvement of cd17 cells in the development of psoriasiform dermatitis suggests that innate immune responses rather than an autoimmune reaction are important for the development of psoriatic dermatitis.
The involvement of Vc6 + cd17 cells in the pathogenesis of uveoretinitis in Aire-deficient mice, a model of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APCED), is suggested, because Vc6 + cd17 thymocytes are expanded due to high levels of IL-7 expression in Aire À/À medullary thymic epithelial cells. 44 Importantly, expansion of IL-17-producing Vc9 + /Vd2 + cd T cells is observed in APCED patients, suggesting the involvement of cd17 cells in these patients. cd17 cells are also implicated in the pathogenesis of spondyloarthritis; the CD27 À cd T-cell population is increased in the Achilles tendon after over-expression of IL-23, which induces spondyloarthritis-like enthesitis in mice. 65 The Vc4 + subset produces IL-17 in the skin grafts and in the host epidermis around grafts, suggesting the involvement in skin graft rejection. 66 Vc4 + cell-derived IL-17 promotes the accumulation of mature dendritic cells in the draining lymph nodes to subsequently increase Th17 cells after skin graft transplantation. 66 
Migration of cd17 cells to inflammatory sites
Trafficking of cd17 cells to the inflammatory sites is important for the development of inflammation. Naive ab T cells express a chemokine receptor CCR7, which is important for homeostatic circulation; its expression is down-regulated during differentiation and the inflammatory chemokine receptor CCR6 is induced on Th17 cells instead. CCR6 + Th17 cells are recruited by CCL20 to cause inflammation, as shown in SKG mice 67 and the EAE model. 68, 69 On the other hand, a gene array analysis shows that the expression of chemokine receptors such as CCR6, CCR2 and CXCR6 is already up-regulated in cd17 cells during thymic development. 34 Recent studies have indicated that the CCL20-CCR6 axis is mainly required for cd17 cell recruitment into homeostatic sites such as dermis, 70 whereas the CCL2-CCR2 axis recruits cd17 cells into inflammatory sites, including psoriatic skin, 71 arthritic joints, 20 central nervous system in EAE, infected mucosal tissues and tumours. 70 Interestingly, cd17 cells constitutively express both CCR2 and CCR6, but downregulate CCR6 expression after inflammation. 70 This is consistent with the 'ready-to-go' nature of cd17 cells and suggests a cd17 cell-recruiting mechanism in which cd17 cells are released from the tissue-specific harness to migrate into inflammatory sites by reducing the tissuespecific homing receptor.
cd17 cells in tumours
Pro-tumour function of cd17 cells has been demonstrated in several cancer models, including a breast cancer metastasis model 72 and an ovarian cancer model, 73 and the roles of cd17 cells in the development of tumours have been reviewed elsewhere. 74 tumour clinicopathological features, suggesting that cd17 cells induce myeloid-derived suppressor cell-mediated immunosuppression. 75 On the other hand, anti-tumour function of cd17 cells after therapeutic treatment has also been reported. cd17 cells infiltration is observed when bladder cancer is treated by intravesical injection of Mycobacterium bovis bacillus Calmette-Gu erin, (BCG) and these cells are protective against tumour development by recruiting neutrophils. 76 Moreover, cd17 cell infiltration in epithelial tumours is observed after chemotherapy and cd17 cells enhance the recruitment of IFN-c-producing CD8 + T cells that mediate the antitumour function.
cd17 cells in pathogen clearance
Interleukin-17 plays protective roles against bacterial and fungal infection by recruiting neutrophils, activating T cells and inducing antimicrobial peptides and inflammatory cytokines.
1,4,5 cd17 cells produce much more IL-17 than Th17 cells after Mycobacterium tuberculosis 78 or Mycobacterium bovis BCG infection. 79 Expression of IL-17 is detected in lungs from the first day after infection with BCG and induces not only neutrophil-mediated inflammation but also granuloma formation. 79 Dermal cd T cells also produce IL-17 at the first day after intradermal BCG infection and induce neutrophil recruitment and antigen-specific CD4 + T-cell expansion. 80 Rapid IL-17 production by Vd1 + T cells is also observed in the peritoneum after intraperitoneal infection with Escherichia coli, followed by neutrophil recruitment.
81 cd17 cells are also found in the liver after Listeria monocytogenes infection 82 and in lungs after Klebsiella pneumoniae infection. + natural Th17 cells within 1-2 days after oral C. albicans infection. 85 As IL-17 production in cd T cells is found at the early stage after infection, cd17 cells are suggested to play an important role in early host defence before establishment of acquired immunity. In humans, patients carrying mutations in either STAT3, IL-17RA, or IL-17F or producing anti-IL-17F autoantibodies are also highly susceptible to skin infection with Staphylococcus aureus and C. albicans. 86, 87 However, the involvement of cd17 cells in host defence in humans against these pathogens remains to be elucidated.
Recently, pathogen-specific memory cd T cells have been implicated in several infection models. Memory cd T cells are elicited in mesenteric lymph nodes after oral L. monocytogenes infection and contribute to clearance of the bacteria by promptly producing IL-17 after secondary infection. 88 
cd17 cells in human inflammatory diseases
Although it has been thought that psoriasis is caused by an autoimmune mechanism, 91 recent studies using mouse models suggest the involvement of innate immunity. 92 High frequency of cd T cells is detected in psoriasiform dermal lesions in mice induced by IMQ, and these cells produce IL-17 through stimulation with IL-23, 23 indicating the innate immune nature of the disease. cd T cells, especially Vc9 + Vd2 + cells which can produce IL-17, are also accumulated in the skin of patients with psoriasis. 93 In this report, however, Vc9 + Vd2 + cells were activated to produce cytokines from keratinocytes by the specific antigen, suggesting that recognition of specific antigens may be important for the development of psoriasis. Because Th17 cells 94 and ILC3s 95 as well as cd17 cells 91 are also detected in the psoriatic skin, the involvement of autoimmunity and the main source of IL-17 during the development of psoriasis still remain obscure in humans.
Recently, several antibodies targeting IL-17 and its receptor have been approved or are in clinical trials for the treatment of psoriasis and psoriatic arthritis. 96 Secukinumab, an anti-IL-17 antibody, has been approved in Japan in 2014 and by the US Food and Drug Administration in 2015 for the treatment of psoriasis and psoriatic arthritis. Treatment with secukinumab for psoriasis patients in a phase III trial shows that more than half of the patients accomplish almost complete remission after 12 weeks of treatment, as determined by the Psoriasis Area and Severity Index (PASI 90), and show better efficacy than a tumour necrosis factor inhibitor (etanercept). 11 Ixekizumab, another monoclonal antibody against IL-17, and Brodalumab, a monoclonal antibody against IL-17RA, are also effective for the treatment of psoriasis in phase III trials 12, 13 and approved for the treatment of psoriasis. Secukinumab has also been approved for the treatment of ankylosing spondylitis. 97 As described, the importance of IL-17 in the development of rheumatoid arthritis (RA) is suggested in mouse models and cd17 cells are accumulated in arthritic joints, 7, 20, 22, 24 but the importance of cd17 cells in patients 98 However, the predominance of IFN-c-producing cd T cells instead of cd17 cells in affected joints is reported elsewhere. 24 This discrepancy may result from the differences of medical treatment and/or stages of RA. Because the efficacy of anti-IL-17 treatment of RA is moderate except for some patients with specific HLA types, 99, 100 cd17 cells may not play crucial roles in the development of RA in humans. Further studies in patients with RA are necessary.
Elevated IL-17 expression in cd T cells, but not CD4 + T cells, was found in patients with systemic juvenile idiopathic arthritis, 101 and IL-17 production was detected in CD161 hi CCR6 + cd T cells in cerebrospinal fluid of patients with MS. 102 Treatment of patients with MS with secukinumab non-significantly reduced the number of combined unique active lesions and significantly reduced the number of cumulative new gadolinium-enhancing T1 lesions by 67%. 103 Further studies are necessary to elucidate the role of cd17 cells in the development of these diseases.
Concluding remarks
In this review, we discussed the development and the function of cd17 cells and the roles of cd17 cells in inflammatory/autoimmune diseases and host defence against pathogens. However, several important questions still remain to be elucidated. The function of TCR signalling in the thymic development of cd17 and the functional roles of TCR signalling in the periphery upon infection and inflammation are not completely elucidated. Elucidation of epigenetic modifications of genes in 'natural' and 'inducible' cd17 cells may provide important information. Discovery of cd17 cell-specific markers may provide a more efficient approach to induce cd17 cell-specific dysfunction in inflammatory diseases without affecting systemic Th17 cells. Most importantly, it is not clear how well mouse disease models represent the pathogenesis of human diseases, especially those of psoriasis, MS and RA. In the case of psoriasis, inhibition of IL-17 signalling efficiently cures the symptoms both in psoriasis patients and IMQ-induced psoriasis models, suggesting that cd17 cells play important roles in both humans and mice. However, in MS and RA, in which the involvement of cd17 is suggested by mouse models, the therapeutic effects of anti-IL-17 are not so drastic as indicated by these models, suggesting that the pathogenic mechanisms may be different in some parts between diseases in humans and mice. Clearly, further analysis of pathogenic mechanisms in patients is necessary to explain this discrepancy.
